文献速递MDS 与骨髓增殖性肿瘤白血病

整合突变谱可能降低原始细胞计数在低危骨髓增生异常肿瘤预后判断中的重要性

Incorporation mutational profile might reduce the importance of blast count in prognostication of low-risk myelodysplastic syndromes.
PubMed 文献 · Br J Haematol · 2024-08-28

该研究纳入227例低危骨髓增生异常肿瘤(LR-MDS)患者,以总生存(OS)和白血病进展概率为主要终点,评估分子病变的预后作用。结果显示RUNX1与较低OS相关,SF3B1与死亡风险降低相关;TP53和RUNX1突变可预测白血病进展;原始细胞百分比无论作为分类变量还是连续变量,对生存和进展概率均无显著影响。

要点

  • RUNX1突变与较低OS相关,SF3B1突变与死亡风险降低相关
  • TP53和RUNX1突变是白血病进展概率的预测协变量
  • 原始细胞百分比对生存和进展概率均无显著影响

核心结论

  • 整合分子数据后,原始细胞百分比在LR-MDS患者中对生存和进展概率均失去临床意义。

研究设计与样本

  • 研究纳入227例低危骨髓增生异常肿瘤(LR-MDS)患者,以总生存(OS)和白血病进展概率为主要终点。

主要发现

  • RUNX1与较低OS相关(HR:1.7,95%CI 1.1-2.9;p=0.05)。
  • SF3B1与死亡风险降低相关(HR:0.23,95%CI 0.1-0.5;p<0.001)。
  • TP53和RUNX1突变是白血病进展概率的预测协变量(p<0.001)。
  • 原始细胞百分比按分类变量分析(<5% vs 5%-9%;HR:1.3,95%CI 0.7-2.9;p=0.2)对生存无显著影响。
  • 原始细胞百分比按连续变量分析(HR:1.07,95%CI 0.9-1.1;p=0.07)对生存无显著影响;对进展概率亦无显著影响(sHR:1.05,95%CI 0.9-1.1;p=0.2)。

关键数值与推荐

  • 按WHO 2022和ICC分类将分析限制于<5%原始细胞的LR-MDS定义时,上述结果仍保持统计学显著性。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Addition of molecular data to prognostic models has improved risk stratification of myelodysplastic neoplasms (MDS). However, the role of molecular lesions, particularly in the group of low-risk disease (LR-MDS), is uncertain. We evaluated a set of 227 patients with LR-MDS. Overall survival (OS) and probability of leukaemic progression were the main endpoints. RUNX1 was associated with lower OS and SF3B1 with a reduced risk of death (HR: 1.7, 95% CI, 1.1-2.9; p = 0.05; and HR: 0.23, 95% CI 0.1-0.5; p < 0.001; respectively). TP53 and RUNX1 mutations were predictive covariates for the probability of leukaemic progression (p < 0.001). Blast percentage, neither analysed as categorical (<5% vs. 5%-9%; HR: 1.3, 95% CI, 0.7-2.9; p = 0.2) nor as a continuous variable (HR: 1.07, 95% CI, 0.9-1.1; p = 0.07), had impact on survival or probability of progression (sHR: 1.05, 95% CI, 0.9-1.1; p = 0.2). These results retained statistical significance when analysis was restricted to the definition of LR-MDS according to the WHO 2022 and ICC classifications (<5% blasts). Thus, with the incorporation of molecular data, blast percentage happens to lose clinical significance both for survival and probability of progression in the group of patients with LR-MDS.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. García-Culebras M, Alcalde P, Márquez-Malaver FJ, et al. Incorporation mutational profile might reduce the importance of blast count in prognostication of low-risk myelodysplastic syndromes. Br J Haematol. 2024. PMID: 39197431. doi:10.1111/bjh.19714

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。